Par Drugs And Chemicals Limited has informed the Exchange about Action(s) initiated or orders passed

Sebi InvestigationRegulatory & Legal View source PDF Explain this filing

PAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.0%Reaction day

₹98.98

prior close

₹97.50

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%-0.7% vs market

Pharmaceuticals peers, median of 148sector-0.5%-0.5% vs sector

On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

-0.1

15m

+0.0

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.0-0.3-0.7-0.5-0.5

Next day

-0.6-0.0-0.6-0.5-0.1

-2.4-1.0-1.4-1.8-0.6

-3.0-1.3-1.7-2.6-0.4

-3.6-3.1-0.5-4.0+0.4

-2.2-2.8+0.6-3.6+1.4

-1.5-2.1+0.6-3.1+1.6

15d

-3.4+1.6-5.0-0.1-3.4

-4.2+1.4-5.7+0.3-4.5

+2.1-2.7+4.8-4.5+6.6

+7.1+0.1+7.0-3.4+10.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Par Drugs and Chemicals Limited has disclosed that SEBI's Corporation Finance Investigation Department has asked the company to attend a meeting on June 18, 2025 at SEBI Bhavan in Mumbai. The meeting relates to the company's earlier announcement on February 14, 2025 about a Slump Sale agreement with Phal-Jig Fine Chemicals Private Limited, involving transfer of land, building, plant & machinery, and specific current assets and liabilities. SEBI wants to discuss this slump sale transaction further. The communication was received by the company on June 12, 2025 via email. The company has stated that no violations or contraventions have been alleged and there is no financial or operational impact at this stage.

Likely market impact

The development signals regulatory scrutiny of the slump sale transaction, which could create uncertainty for shareholders. However, since the company has not been charged with any violation yet and no financial impact has been quantified, the immediate market impact is likely to be limited. Investors should watch for outcomes of the June 18 meeting.